{"id":61844,"date":"2026-03-30T16:43:41","date_gmt":"2026-03-30T08:43:41","guid":{"rendered":"https:\/\/flcube.com\/?p=61844"},"modified":"2026-03-30T16:43:42","modified_gmt":"2026-03-30T08:43:42","slug":"jjs-icotyde-sustains-and-improves-complete-skin-clearance-in-psoriasis-through-52-weeks-outperforming-deucravacitinib-on-safety","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61844","title":{"rendered":"J&J\u2019s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety"},"content":{"rendered":"\n

Johnson & Johnson<\/strong> (J&J, NYSE: JNJ<\/a>) released 52-week long-term data<\/strong> from the Phase III ICONIC-ADVANCE 1\/2 and ICONIC-LEAD trials<\/strong>, demonstrating that Icotyde\u2122 (icotrokinra)<\/strong>\u2014the world\u2019s first and only targeted oral peptide blocking the IL-23 receptor<\/strong>\u2014achieved sustained and improving complete skin clearance (PASI 100)<\/strong> in adults with moderate-to-severe plaque psoriasis (PsO)<\/strong>. Patients on continuous Icotyde saw PASI 100 rates rise from 41% to 49%<\/strong> (ADVANCE 1) and 33% to 48%<\/strong> (ADVANCE 2) between Weeks 24 and 52. Those who switched from placebo to Icotyde at Week 16 reached comparable clearance rates by Week 52<\/strong>, reinforcing the drug\u2019s durability and reversibility of delay. Critically, Icotyde showed a favorable safety profile through 52 weeks<\/strong>, with lower overall adverse event and infection rates versus deucravacitinib<\/strong> at Week 24.<\/p>\n\n\n\n

Long-Term Efficacy Highlights (Week 52)<\/h2>\n\n\n\n
Study Arm<\/th>PASI 100 at Week 24<\/th>PASI 100 at Week 52<\/th>Trend<\/th><\/tr><\/thead>
Icotyde (ADVANCE 1)<\/strong><\/td>41%<\/td>49%<\/strong><\/td>\u2191 +8 ppt<\/td><\/tr>
Icotyde (ADVANCE 2)<\/strong><\/td>33%<\/td>48%<\/strong><\/td>\u2191 +15 ppt<\/td><\/tr>
Placebo \u2192 Icotyde (switch at W16)<\/strong><\/td>\u2014<\/td>50% (ADV1) \/ 43% (ADV2)<\/strong><\/td>Matches continuous therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The continued improvement beyond 24 weeks suggests progressive tissue remodeling and immune normalization<\/strong>\u2014a hallmark of deep IL-23 pathway inhibition.<\/p>\n\n\n\n

Safety Profile Advantage<\/h2>\n\n\n\n
Metric (Through Week 24)<\/th>Icotyde<\/th>Deucravacitinib<\/th><\/tr><\/thead>
Overall Adverse Events<\/strong><\/td>Lower<\/td>Higher<\/td><\/tr>
Infection Rates<\/strong><\/td>Lower<\/td>Higher<\/td><\/tr>
New Safety Signals (through W52)<\/strong><\/td>None identified<\/strong><\/td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

With no new safety signals emerging through one full year<\/strong>, Icotyde reinforces its potential as a best-in-class oral IL-23\u2013targeted therapy<\/strong>, distinct from small-molecule TYK2 inhibitors.<\/p>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n